[Federal Register Volume 85, Number 43 (Wednesday, March 4, 2020)]
[Notices]
[Page 12811]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-04408]
=======================================================================
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes Charter
Renewal
AGENCY: Nuclear Regulatory Commission.
ACTION: Notice of renewal of the charter of the Advisory Committee on
the Medical Uses of Isotopes.
-----------------------------------------------------------------------
SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) has determined
that renewal of the charter for the Advisory Committee on the Medical
Uses of Isotopes (ACMUI) until February 28, 2022, is in the public
interest in connection with duties imposed on the Commission by law.
This action is being taken in accordance with the Federal Advisory
Committee Act, after consultation with the Committee Management
Secretariat, General Services Administration.
The purpose of the ACMUI is to provide advice to the NRC on policy
and technical issues that arise in regulating the medical use of
byproduct material for diagnosis and therapy. Responsibilities include
providing guidance and comments on current and proposed NRC regulations
and regulatory guidance concerning medical use; evaluating certain non-
routine uses of byproduct material for medical use; and evaluating
training and experience of proposed authorized users. The members are
involved in preliminary discussions of major issues in determining the
need for changes in NRC policy and regulation to ensure the continued
safe use of byproduct material. Each member provides technical
assistance in his/her specific area(s) of expertise, particularly with
respect to emerging technologies. Members also provide guidance as to
NRC's role in relation to the responsibilities of other Federal
agencies as well as of various professional organizations and boards.
Members of this Committee have demonstrated professional
qualifications and expertise in both scientific and non-scientific
disciplines including nuclear medicine; nuclear cardiology; radiation
therapy; medical physics; nuclear pharmacy; State medical regulation;
patient's rights and care; health care administration; and Food and
Drug Administration regulation.
Contact Information: Kellee Jamerson, Office of Nuclear Material Safety
and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC
20555; Telephone: (301) 415-7408 or at [email protected].
Dated: February 28, 2020.
Russell E. Chazell,
Federal Advisory Committee Management Officer.
[FR Doc. 2020-04408 Filed 3-3-20; 8:45 am]
BILLING CODE 7590-01-P